Back

Effect of stereotactic body radiation therapy on left ventricular diastole function in symptomatic patients with hypertrophic obstructive cardiomyopathy

2 September 2024 (14:00 - 14:40)
Organised by: Logo
Congress Presentation Part of: Phenotyping left ventricular hypertrophy: what's new? Systolic and Diastolic Function ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Na Liu

The Second Xiangya Hospital of Central South University, Changsha (China)

6 More presentations in this session

Presentation thumbnail
Association between impaired left ventricular global longitudinal strain and B-type natriuretic peptide in obstructive hypertrophic cardiomyopathy
Associate Professor Z. Wang (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Assessing the utility of the increased wall thickness score in diagnosing ATTR cardiomyopathy: a validation study
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Left ventricular hypertrophy, wall thickness, and histological myocyte alteration in end-stage heart failure: a call for a standard definition
Mr J. Bhumitrakul (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Residual mitral leaflet length independently indicates left ventricular outflow tract obstruction in hypertrophic cardiomyopathy
Doctor D. Zach (Salzburg, AT)
Abstract Slides Video
Presentation thumbnail
Differential echocardiographic profiles in immunoglobulin light chain and transthyretin amyloid cardiomyopathy: insights from speckle tracking analysis
Doctor Y. Saijo (Tokushima, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Phenotyping left ventricular hypertrophy: what's new?

The Event

Event poster

ESC Congress 2024

2 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Session
Hypertrophic cardiomyopathy: from gene to treatment
thumbnail
Congress Session
Precision medicine in hypertrophic cardiomyopathy
thumbnail
Congress Session
Contemporary management of hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources